Clinical Trial: Long-Term Safety Study of Deucravacitinib Versus Ustekinumab in Participants With Psoriasis (PRAGMATYK)

U.S., Aug. 13 -- ClinicalTrials.gov registry received information related to the study (NCT07116967) titled 'Long-Term Safety Study of Deucravacitinib Versus Ustekinumab in Participants With Psoriasis (PRAGMATYK)' on Aug. 04.

Brief Summary: A study to evaluate the long-term safety of Deucravacitinib versus Ustekinumab in participants with psoriasis

Study Start Date: Oct. 30

Study Type: INTERVENTIONAL

Condition: Plaque Psoriasis

Intervention: DRUG: Deucravacitinib

Specified dose on specified days

DRUG: Ustekinumab

Specified dose on specified days

Recruitment Status: NOT_YET_RECRUITING

Sponsor: Bristol-Myers Squibb

Published by HT Digital Content Services with permission from Health Daily Digest....